Transforming patients' lives through science™



12/20
of our blockbuster drugs are derived from collaborations

60%
of development pipeline are externally sourced

300+
active alliances

Bristol Myers Squibb™

bms.com/partnering **Business Development**

Bristol Myers Squibb™

Therapeutic Areas of Focus

Solid Tumors

Bristol Myers Squibb is at the forefront of oncology with an extensive portfolio of investigational compounds and approved medicines

- Our focus is to leverage a deeper understanding of tumor biology and translational approaches that will lead to the right treatments for the right patients at the right time
- We are pursuing novel therapies with the potential to be transformational to existing standards of care
- We seek opportunities in patient populations not currently addressable by checkpoint blockade
- In IO-responsive tumors, we seek to increase response rates, deepen responses and/or extend the durability of response

Areas of interest include, but are not limited to, the following:

- Direct tumor-targeting agents
- Tumor intrinsic biology with clear patient selection strategy
- Novel innate and adaptive immune mechanisms
- Novel mechanisms that address primary or acquired resistance to cancer immunotherapy

Compound/Brand Name	Phase	Modality	External
AHR Antagonist (Ikena)	1	Small Molecule	■
Anti-CD73	1	Biologic	
Anti-CTLA-4 NF-Probody	1	Biologic	
Anti-Fucosyl GM1	1	Biologic	
Anti-IL8	1	Biologic	■
Anti-NKG2A	1	Biologic	
Anti-OX40	1	Biologic	
Anti-SIRPα *	1	Biologic	■
Anti-TIGIT	1	Biologic	
Anti-TIM3	1	Biologic	
AR-LDD	1	Small Molecule	■
CD3xPSCA (GEMoaB)+	1	Biologic	■
IL-12 Fc	1	Biologic	■
Motolimod	1	Small Molecule	■
NLRP3 Agonist	1	Small Molecule	■
STING Agonist	1	Small Molecule	■
TGFβ Inhibitor	1	Biologic	■
LSD1 inhibitor *	2	Small Molecule	■
Anti-CTLA-4 NF	2	Biologic	
Anti-CTLA-4 Probody	2	Biologic	■
CCR2/5 Dual Antagonist	2	Small Molecule	
Marizomib	3	Small Molecule	■
Linrodostat	3	Small Molecule	■
Bempegaldesleukin+	3	Biologic	■
Relatlimab *+	3	Biologic	
Ipilimumab, YERVOY®+	M	Biologic	■
Nivolumab, OPDIVO®+	M	Biologic	■
Paclitaxel, ABRAXANE®	M	Small Molecule	■

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. We are focused on our core therapeutic areas and are pursuing multiple drug platforms across these areas with a goal of transforming patients' lives through science. External innovation and partnering are critical drivers of our strategy and have brought significant commercial success and pipeline growth.

Hematology

Bristol Myers Squibb is committed to sustaining its strong leadership and legacy in the development of transformational therapeutics for treating patients with malignant and benign hematological conditions

- Our focus is on Multiple Myeloma, Lymphoma and CLL, MDS, AML, MPNs (e.g., myelofibrosis), thalassemias, and benign hematology

Areas of interest include, but are not limited to, the following:

- Protein homeostasis/degradation
- Epigenetics
- ADCs, Bispecifics (e.g., T-cell/NK cell engagers), and other novel antibody constructs
- Adoptive cell therapies
- Novel therapeutic combinations
- Other potentially transformative new targets and pathways
- Other potentially transformative modalities (e.g., tumor phagocytosis)

Compound/Brand Name	Phase	Modality	External
A/I CELMoD (CC-92480)	1	Small Molecule	
CD22 ADC (TriPhase)	1	Biologic	■
BCMA TCE	1	Biologic	■
BCMA CAR T (bb21217)+	1	Cell Therapy	■
BCMA ADC	1	Biologic	■
GSPT1 CELMoD (CC-90009)	1	Small Molecule	
BET Inhibitor* (CC-90010)	1	Small Molecule	■
BET Inhibitor* (CC-95775)	1	Small Molecule	■
BET Inhibitor (BMS-986158)	1	Small Molecule	
A/I CELMoD (CC-99282)	1	Small Molecule	
CD3x33 (GEMoaB)+	1	Biologic	■
GPRC5D CAR T	1	Cell Therapy	■
BCMA NEX T	1	Cell Therapy	■
CD19 NEX T	1	Cell Therapy	■
Orva-cel	2	Cell Therapy	■
Iberdomide	2	Small Molecule	
Liso-cel	3	Cell Therapy	■
Ide-cel+	3	Cell Therapy	■
Luspatercept, REBLOZYL+	M	Biologic	■
Pomalidomide, POMALYST*	M	Small Molecule	
Enasidenib, IDHIFA+	M	Small Molecule	■
Fedratinib, INREBIC	M	Small Molecule	■
Lenalidomide, REVLIMID	M	Small Molecule	
Elotuzumab, EMPLICITI+	M	Biologic	■
Romidepsin, ISTODAX	M	Small Molecule	■
Dasatinib, SPRYCEL	M	Small Molecule	
Azacitidine, ONUREG	M	Small Molecule	■

Cardiovascular

Bristol Myers Squibb is committed to continuing its strong leadership and legacy in the development of transformational therapeutics for treating patients with cardiovascular disease

- Our focus is both chronic and acute heart failure, with particular interest in patients with heart failure with preserved ejection fraction

Areas of interest include, but are not limited to, the following:

- Protection against or regression of adverse remodeling of the heart, including: fibrosis, hypertrophy, resolution of inflammation, cardiomyocyte preservation or regeneration
- Improvement of peripheral vascular compliance
- Preservation or improvement of renal function/renal perfusion in heart failure patients
- Enhancement of cardiac function, including improvements in contraction or relaxation
- Drug targets not readily amenable to current approaches
- Novel technologies supporting clinical development of new heart failure therapies
- Novel targets and /or agents addressing specific cardiomyopathies (e.g., genetically defined and amyloidosis-related)
- Clinical stage opportunities (Phase 2/3)
  - Novel mechanisms for Atherosclerosis and Antiarrhythmic agents

Compound/Brand Name	Phase	Modality	External
FA-Relaxin	1	Biologic	■
FPR-2 Agonist	1	Small Molecule	
Factor XIa Inhibitor (BMS-986209)+	1	Small Molecule	
MYK-224	1	Small Molecule	■
Factor XIa Inhibitor (BMS-986177)+	2	Small Molecule	
Danicamtiv	2	Small Molecule	■
Mavacamten	3	Small Molecule	■
Apixaban, ELIQUIS®+	M	Small Molecule	

Immunology

At Bristol Myers Squibb, our expertise in immune-mediated disease began over 20 years ago and is grounded in discovering and developing therapies that help to modulate the body's immune response

- Bristol Myers Squibb has an industry-leading pipeline, including discovery and clinical stage first-in-class agents spanning multiple pathways, mechanisms and approaches which are being developed internally and through partnerships and collaborations
- Our goal is to deliver life-changing medicines for patients with a focus on therapies that have transformative potential in rheumatology, gastroenterology, dermatology and neurology; this includes rheumatoid arthritis, systemic lupus erythematosus (SLE)/ lupus nephritis, inflammatory bowel disease (IBD), atopic dermatitis, psoriasis, multiple sclerosis and other immune-mediated diseases with high unmet needs, that can be used either alone or in combinations

Areas of interest include, but are not limited to, the following:

- Agents that target selective immune suppression, eliminate pathogenic immune memory cells and/or promote immune homeostasis, including those that act on both immune and non-immune cell types (e.g., epithelial and stromal cells)
- Novel therapeutic modalities that selectively modulate genetically validated targets
- Biomarkers of disease activity to inform patient stratification, measure pharmacodynamic responses and predict efficacy, with a particular interest in such biomarker-enabled programs

Compound/Brand Name	Phase	Modality	External
IL2 Mutein	1	Biologic	■
S1PR1 Modulator	1	Small Molecule	
TLR 7/8 Antagonist	1	Small Molecule	
TYK2 Inhibitor	1	Small Molecule	
MK2 Inhibitor	1	Small Molecule	■
TYK2 Inhibitor (Nimbus)	1	Small Molecule	■
Imm. Tolerance (Anokion)	1	Small Molecule	■
Branebrutinib	2	Small Molecule	
Iberdomide	2	Small Molecule	
Cendakimab	2	Biologic	■
Deucravacitinib (TYK2 Inhibitor)	3	Small Molecule	
Ozanimod, ZEPOSIA	M	Small Molecule	■
Abatacept, ORENCIA®+	M	Biologic	
Belatacept, NULOJIX®	M	Biologic	

Fibrotic Diseases

Bristol Myers Squibb is committed to the development of transformational therapeutics to treat patients with advanced fibrotic diseases of the liver or lung. Areas of interest include, but are not limited to, the following:

- Advanced liver fibrosis (stage F3/F4) due to nonalcoholic steatohepatitis (NASH), or primary sclerosing cholangitis
- Progressive pulmonary fibrotic diseases including Idiopathic Pulmonary Fibrosis and non-IPF Interstitial Lung Diseases such as scleroderma
- Mechanisms which promote repair and reversal of fibrosis through inhibition of inflammatory responses, protection of epithelium and normalization of fibroblast activation
- Non-invasive biomarkers of disease activity and progression, patient stratification, prediction of efficacy and pharmacodynamic response

Compound/Brand Name	Phase	Modality	External
LPA1 Antagonist (BMS-986337)	1	Small Molecule	
NME	1	Small Molecule	
JNK Inhibitor	2	Small Molecule	
HSP47*	2	Small Molecule	■
Pegbelfermin	2	Biologic	■
LPA1 Antagonist (BMS-986278)	2	Small Molecule	■

Neuroscience

Bristol Myers Squibb is committed to the development of transformational therapeutics for patients with neurodegenerative and neuromuscular diseases

- We have built a network of external partnerships across multiple treatment platforms (small molecules, biologics and nucleic acid targeting) that leverage our leadership in protein homeostasis, immunology and inflammation to attack neurological and neuromuscular diseases

Areas of interest include, but are not limited to, the following:

- Disease-modifying therapies for neurodegenerative, neuroimmune, neuro-inflammatory and neuromuscular diseases (e.g., Alzheimer's, Parkinson's, and Lou Gehrig's diseases, Multiple Sclerosis, repeat expansion diseases, muscular dystrophies)
- Targets that modulate protein homeostasis, protein clearance, immune system biology, inflammation and reduce or eliminate toxic protein production
- Emerging technologies (RNA, DNA targeting, gene regulation, editing and replacement, vector optimization) that when matched to underlying disease genetics, can deliver a precision medicine portfolio with a high probability of success to address unmet medical needs
- Targets in sporadic and orphan/rare neurological and neuromuscular diseases
- Translational tools and technologies such as neuroimaging and fluid biomarkers to track neurodegenerative disease
- Novel blood brain-barrier delivery technologies

Compound/Brand Name	Phase	Modality	External
FAAH/MGLL Dual Inhibitor	1	Small Molecule	■

1 - Phase 1 **2** - Phase 2 **3** - Phase 3 **M** - Marketed Product Development
■ - External Innovation: Compound originated from an external source.

* In development for solid tumors and hematology

+ Development Partnership

Bristol Myers Squibb™

For more information please visit: **bms.com/partnering**

Business Development

Cross-Therapeutic Areas of Focus

Translational Medicine

Bristol Myers Squibb is committed to translational medicine approaches to help our patients get the maximum benefit of our drugs. We routinely collaborate with partners to move novel biomarker innovations into clinical practice.

Areas of interest include, but are not limited to, the following:

- Innovative biomarker applications to inform target identification, disease characterization and treatment optimization:
  - Predictive biomarkers and diagnostic approaches
  - Pharmacodynamic assessment of dose and treatment response monitoring
  - Biomarkers of emerging or novel clinical endpoints (e.g., minimal residual disease)
  - Technologies and systems to elucidate disease biology (including the tumor microenvironment) and mechanisms of resistance
- Biomarker and bioanalytical technologies and platforms:
  - Novel histopathology approaches; multiplexed, digital-ready IHC and fluorescence-based platforms
  - Multicolored flow cytometry assays (exploratory and diagnostic grade), for both peripheral and tumoral assessment
  - Metabolomic, proteomic and other high-resolution or high-throughput, bioanalytical technologies
  - Genomics research platforms covering NGS: gene expression profiling and single-cell RNAseq, tumor and germline DNA deep sequencing, methylation and epigenomic profiling, liquid biopsy (cfDNA and cfRNA)
  - Novel imaging capabilities: radiomics, radiographic and alternate tracer platforms

Digital Health

Bristol Myers Squibb is committed to leveraging advances in digital health to better enable and accelerate our discovery, exploratory development, full development and commercialization of our products.

Capabilities of interest include, but are not limited to, the following:

- Identify early pipeline differentiation through translational medicine
- Accelerate and deliver on our robust clinical trial portfolio
- Enhance our therapeutics and deliver better outcomes to patients and providers
- Foster quality patient-clinician interactions that are meaningful and personalized
- Provide bioinformatics and data analytics:
  - Machine-learning/AI pathology approaches and computational biology technologies/ platforms; neoantigen modeling and other validated biomarker predictive algorithms
  - General bioinformatics and internal/ external database semantic-integration technologies
  - Proprietary genomic, metabolomic, or proteomic or other high density-information databases and search tools, including real-world integrated molecular and clinical data repositories

Drug Platforms and Modalities

Biologics

Drug Delivery Technology

Small Molecules

"We are open to a wide range of partnership opportunities focused on innovative medicines and we are committed to being a leading biopharma partner."

– Elizabeth Mily
Executive Vice President,
Strategy and Business Development

Cell Therapy

Bristol Myers Squibb is committed to building a leadership position in cell therapy by leveraging unparalleled disease expertise, CMC capabilities, manufacturing scale and portfolio of first/best-in-class assets.

- Our focus is on developing adoptive cell therapies providing transformative outcomes to patients with both hematologic and solid tumor malignancies

Areas of interest include, but are not limited to, the following:

- Allogeneic cell platforms – donor/iPSC, NK cells
- Gamma delta T cells
- Additional cell types – e.g., macrophages, NKT cells
- Novel tumor targets and binders – CAR and TCR
- Next-generation engineering (e.g., CAR logic gates, gene editing, TME modulation)
- Non-viral delivery for modifying cell gene expression
- Enabling manufacturing platforms and technologies
- Combinations with other therapies to increase efficacy

Research Technologies

Bristol Myers Squibb is committed to enhancing our discovery and development efforts through innovative technologies.

Areas of interest include, but are not limited to, the following:

- Access to new chemical matter, including macrocycle and fragment libraries
- Novel discovery platforms, including target discovery modalities
- Emerging protein structure determination platforms
- Microfluidics based platforms
- Super resolution imaging platforms (such as 3D bioprinter, intelligent image analysis tools, tissue imaging and real-time single cell sorting/ purification based on machine learning)
- Technologies directed toward enhancing GI absorption of poorly absorbed compounds or enabling novel delivery methods (colonic, intraoral, subcutaneous, intra-tumoral)
- Solid state stabilization of proteins to enable high-concentration parenteral delivery
- Controlled release technologies for drug delivery
- Drug delivery device technologies
- Machine learning capabilities applied to research and early development
- Label-free cellular target engagement platforms
- Single cell genomics and proteomic platforms
- Systems biology tools to evaluate pharmacologic/toxicologic responses
- Translationally relevant preclinical models
- Companion digital therapeutics that enhance delivery of care
- ADCs: novel targets, including post-translationally modified forms, with a strong link to cancer biology and reasonable pre-clinical data
- Novel MOA payloads including TOPO1 inhibitors
- Technologies that can enhance internalization and trafficking to lysosomes

Antibody Drug Conjugates

Millamolecules

Gene Therapy

RNA Oligonucleotides

Cell Therapy

Protein Homeostasis

> "Bristol Myers Squibb was the right partner who brought the optimal deal structure, considerable capabilities and a commitment of resources."

> "We had a number of attractive strategic options in front of us, however Bristol Myers Squibb and its focus on exploring our biology won the day."

RECENT TRANSACTION PARTNERS

Business Development Contacts

Below please find a list of contacts for each area of interest.
To learn more about our team, please visit the website:
bms.com/partnering

Solid Tumors
BD-Onc@bms.com
Fang Zhang

Neuroscience
BD-NeuroCV@bms.com
Neuroscience –
Eva Chmielnicki

Cardiovascular, Fibrosis & Immunology
David Harden

Cardiovascular
BD-NeuroCV@bms.com

Fibrosis & Immunology
BD-FibImm@bms.com

Hematology & Cell Therapy
BD-HemaCT@bms.com
Hematology –
Wendy Thompson

Cell Therapy –
Katarzyna Urbanska

Translational Medicine
BD-PDxBiomarkers@bms.com
John Beeler

Research Enabling Technologies
BD-RET@bms.com
Michael Cucolo

Digital Health Initiatives
BD-DHI@bms.com
Michael McInerney

Bristol Myers Squibb™

For more information please visit: **bms.com/partnering**

"Both internal and external innovation are critical components of our mission to bring transformational medicines to patients."

– Giovanni Caforio, M.D.
Chief Executive Officer